Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Nat Methods. 2013 Feb 10;10(3):243–245. doi: 10.1038/nmeth.2366

Figure 2.

Figure 2

Activities of 16 TALE activators targeted to the endogenous human VEGF-A, miR-302/367 cluster, and NTF3 genes. For all three gene targets, experiments were performed in triplicate with TALE activators harboring either the VP64 (green bars) or NF-KB p65 (blue bars) activation domain. Error bars represent standard errors of the mean. (a) VEGF-A-targeted TALE activators. Fold-activation values of VEGF-A protein were determined as described in Methods. Asterisks indicate activators that induced fold-activation of VEGF-A significantly greater than 1, as determined by a one-sided, paired t-test (P < 0.05). (b) miR-302/367-targeted TALE activators. Fold-activation values of miR-302a transcript were determined as described in Methods. Asterisks indicate activators that induced fold-activation of miR-302a transcript levels to a level significantly greater than 1 as determined by a one-sided, paired t-test (P < 0.05). (c) NTF3-targeted TALE activators. Expression levels of NTF3 mRNA relative to GAPDH mRNA are shown. Asterisks indicate activators that induced significant elevation of NTF3 transcript levels relative to a control as determined by a one-sided, paired t-test (P < 0.05). (d) Synergistic activation of VEGF-A. Experiments were performed as in (a) except that the amount of DNA used for individual TALE activators was six-fold lower. Asterisks indicate activators that induced fold-activation of VEGF-A significantly greater than 1, as determined by a one-sided, paired t-test (P < 0.05).